Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2024-08-16 Investor Presentation
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is an intimation letter to stock exchanges about an upcoming Investors/Analysts Meeting, including a detailed investor presentation. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content includes company snapshots, business segments, market data, and strategic updates, typical of an investor presentation. The document is about informing the market and investors about the meeting and sharing the presentation materials, not a full financial report or earnings release. It is not a regulatory filing, audit report, or management report. The length and detail correspond to a presentation rather than a brief announcement or a full annual/interim report. Therefore, the document fits best under the category of Investor Presentation (IP).
2024-08-16 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a detailed disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, concerning a put option offer and acquisition-related transaction by Jubilant Biosys Innovative Research Services Pte Limited, a subsidiary of Jubilant Biosys Limited. It includes specifics about the transaction, investment amounts, approvals required, and strategic rationale. The document is not a full financial report, earnings release, or audit report, but rather a regulatory announcement about a significant corporate transaction involving acquisition and investment. It does not contain financial statements or quarterly results but focuses on the transaction details and regulatory compliance disclosures. This fits best under Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes involving equity investment and acquisition of an R&D center.
2024-08-16 English
Copy of Newspaper Publication
AGM Information Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the publication of newspaper advertisements about the Notice of the 46th Annual General Meeting (AGM), e-voting information, record date, and final dividend. It mentions the dissemination of the Notice of the AGM and the Annual Report for the financial year 2023-24 to members. The document itself is not the Annual Report but an announcement about the notice and related information being published and disseminated. The document length is short (1641 characters), and it serves as an announcement rather than the full report or detailed AGM materials. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Report Publication Announcement (RPA). However, since it specifically relates to the notice and e-voting information for the AGM, it aligns more closely with AGM Information (AGM-R). But the document is primarily about the notice publication and e-voting information, which is part of AGM materials. Given the short length and nature, it is best classified as AGM Information (AGM-R).
2024-08-09 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a detailed notice for the 46th Annual General Meeting (AGM) of Jubilant Pharmova Limited scheduled for August 30, 2024. It includes the agenda items such as adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2024, declaration of dividend, and appointment of directors. The document also mentions the availability of the Annual Report for the financial year 2023-24 and the AGM notice, with links to download these documents. The text is comprehensive and includes procedural details about e-voting, dividend payment, and regulatory compliance related to the AGM. Since the document primarily serves as the official notice and agenda for the AGM, including e-voting instructions and references to the Annual Report but does not contain the full Annual Report itself, it fits the category of AGM Information (AGM-R). The document length (15,000 characters) and content confirm it is not merely an announcement but the actual AGM notice and related materials. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-08-08 English
Copy of Newspaper Publication
AGM Information Classification · 95% confidence The document is a letter dated August 6, 2024, addressed to stock exchanges informing about the scheduling of the 46th Annual General Meeting (AGM) of Jubilant Pharmova Limited to be held on August 30, 2024. It mentions that the Notice of the AGM and the Annual Report for the financial year 2023-24 will be sent to shareholders and made available on the company's website in due course. The document also encloses copies of newspaper advertisements published pursuant to regulatory requirements. The document does not contain the Annual Report itself, nor detailed financial data or management discussion. It is an announcement related to the AGM and the upcoming report distribution. The document length is short (1993 characters), and it primarily serves as a notification of the AGM date and related procedural information. Therefore, it fits the category of AGM Information (AGM-R) rather than the Annual Report (10-K) or Report Publication Announcement (RPA).
2024-08-06 English
Change in Management
Board/Management Information Classification · 100% confidence The document is an official intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It announces the resignation of a senior management personnel, Dr. Saji Thomas, Vice President & Head-R&D (API), effective August 2, 2024. The document includes details required under the regulation and a resignation letter annexure. There is no financial data, report, or presentation content. The document is clearly an announcement of a change in senior management, fitting the category of Board/Management Information (MANG). The document length is short and focused solely on management change, not a report or other filing type.
2024-08-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.